Friday, July 10, 2026

pharma · Immunotherapy · Opioid Analgesic Adverse Reaction

Second Affiliated Hospital

Second Affiliated Hospital clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

CN HQ
103 Employees
NMPA registrant Type
Company details
Status
Public
HQ
CN
Employees
103
Programs
4
Drugs
11
Patents
0
Intelligence · Clinical Programs

Second Affiliated Hospital projects

4 ClinicalTrials.gov programs sponsored by Second Affiliated Hospital.

Second Affiliated Hospital has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Cadonilimab

    Second Affiliated Hospital of Soochow University

    Immunotherapy

    phase 2 small molecule active

    1 trial
  2. ZZ-IT-ICI-HCC 1line-023

    Second Affiliated Hospital of Soochow University

    Liver Cancer

    phase 2 small molecule active

    1 trial
  3. Vedolizumab

    Second Affiliated Hospital of Soochow University

    Ulcerative Colitis (UC)

    approved mab completed

    1 trial
  4. Esketamine, Sulfentanil or/and Remifentanil

    Second Affiliated Hospital of Soochow University

    Opioid Analgesic Adverse Reaction

    small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Second Affiliated Hospital have?

4 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.